Literature DB >> 22226485

Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995-2007.

Chaoyang Li1, Earl S Ford, Guixiang Zhao, James Tsai, Lina S Balluz, Wayne H Giles.   

Abstract

OBJECTIVE: People with type 2 diabetes may need insulin therapy to compensate for their underlying pathogenic abnormalities and to improve glycemic control. We examined trends of insulin use among US adults aged ≥40 years with type 2 diabetes.
METHODS: We analyzed data from the Behavioral Risk Factor Surveillance System collected annually during 1995-2007. Insulin use was assessed by self-report. Log-linear regression analyses with a robust error variance estimator were performed to estimate the prevalence, prevalence ratios, and their 95% confidence intervals.
RESULTS: The overall crude and age-standardized proportion of insulin use decreased from 35% and 36% in 1995 to 23% and 22% in 2007, respectively. After adjustments for age, sex, race/ethnicity, education attainment, body mass index, and diabetes duration, the overall prevalence decreased from 33% to 22% (P<.0001 for linear trend). The decreasing rates were similar across sex (P=.23 for interaction between sex and survey year) and race/ethnicity (P=.35 for interaction between race/ethnicity and survey year).
CONCLUSION: The proportion of insulin use decreased from 1995 to 2007 among US adults aged ≥40 years. Continuing efforts may be needed to properly identify those who may need to initiate and maintain insulin therapy among patients with type 2 diabetes as medically indicated. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226485     DOI: 10.1016/j.jdiacomp.2011.11.005

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  7 in total

1.  Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011.

Authors:  Sei J Lee; Irena Stijacic-Cenzer; Caroline Barnhart; Keelan McClymont; Michael A Steinman
Journal:  J Am Med Dir Assoc       Date:  2015-08-10       Impact factor: 4.669

2.  Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study.

Authors:  Julie A Schmittdiel; Marsha A Raebel; Wendy Dyer; Stanley Xu; Glenn K Goodrich; Emily B Schroeder; Jodi B Segal; Patrick J O' Connor; Gregory A Nichols; Jean M Lawrence; H Lester Kirchner; Andy J Karter; Jennifer Elston Lafata; Melissa G Butler; John F Steiner
Journal:  J Am Pharm Assoc (2003)       Date:  2014 Jul-Aug

3.  Diabetes distress from the patient's perspective: Qualitative themes and treatment regimen differences among adults with type 2 diabetes.

Authors:  M L Tanenbaum; N S Kane; J Kenowitz; J S Gonzalez
Journal:  J Diabetes Complications       Date:  2016-05-04       Impact factor: 2.852

4.  Comparison of Antidiabetic Regimens in Patients with Type 2 Diabetes Uncontrolled by Combination Therapy of Sulfonylurea and Metformin: Results of the MOHAS Disease Registry in Korea.

Authors:  Sung Hee Choi; Tae Jung Oh; Hak Chul Jang
Journal:  Diabetes Metab J       Date:  2017-05-11       Impact factor: 5.376

5.  Trends in Out-of-Pocket Cost of Glucagon, 2010-2020.

Authors:  Margaret Zupa; Robert Feldman; Jing Luo
Journal:  JAMA Netw Open       Date:  2022-08-01

6.  Management of type 2 diabetes mellitus in older patients: current and emerging treatment options.

Authors:  Etie Moghissi
Journal:  Diabetes Ther       Date:  2013-10-05       Impact factor: 2.945

7.  Real-world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register.

Authors:  Alice P S Kong; Thomas Lew; Eric S H Lau; Lee-Ling Lim; Jothydev Kesavadev; Weiping Jia; Wayne H-H Sheu; Leorino Sobrepena; Alexander T B Tan; Thy Khue Nguyen; Kun-Ho Yoon; Ke Wang; Kamlanathan Kodiappan; Tamás Treuer; Juliana C N Chan
Journal:  Diabetes Obes Metab       Date:  2020-02-03       Impact factor: 6.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.